论文部分内容阅读
本文比较了两种不同菌株的BCG即Pasteur和GlaxoBCG膀胱内灌注预防浅表膀胱癌复发的效果。病人和方法:1984年以来,多次复发,TURBT治疗难以控制的浅表膀胱癌21例,其中男17例,女4例。5例曾膀胱内灌注乙环氧啶(Epodyl)或阿霉素无效。组织学Ⅱ级13例,Ⅲ级2例,低级4例,2例膀胱内为广泛原位癌。所有肿瘤均属浅表(≤PT1.病人随机分为Glaxo BCG组(12例)和Pasteur BCG组(9例),将BCG1.2×10~9集落形成单位溶于100ml N.S中由导尿管灌注。所有能见的膀胱肿瘤均在膀胱镜下
This article compared the effects of intravesical instillation of BCG, Pasteur and GlaxoBCG, on the recurrence of superficial bladder cancer in two different strains. Patients and Methods: Since 1984, many recurrences, TURBT treatment of uncontrolled superficial bladder cancer in 21 cases, including 17 males and 4 females. Five patients who had intravesical instillation of epodyl or doxorubicin had no effect. Tissue grade Ⅱ 13 cases, Ⅲ grade 2 cases, 4 cases of low grade, 2 cases of bladder for a wide range of carcinoma in situ. All tumors were superficial (≤PT1. Patients were randomly divided into Glaxo BCG group (12 cases) and Pasteur BCG group (9 cases). The BCG 1.2 × 10-9 colony forming units were dissolved in 100 ml NS Perfusion All visible bladder tumors were under cystoscopy